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Summary 
Bainbridge-Ropers syndrome is a genetic syndrome caused by heterozygous loss-of-function 
pathogenic variants in ASXL3, which encodes a protein involved in transcriptional regulation.  
Affected individuals have multiple abnormalities including developmental impairment, 
hypotonia and characteristic facial features.  Seizures are reported in approximately a third of 
cases; however, the epileptology has not been thoroughly studied.  We identified three patients 
with pathogenic ASXL3 variants and seizures at Austin Health and in the DECIPHER database.  
These three patients had novel de novo ASXL3 pathogenic variants, two with truncation variants 
and one with a splice site variant.  All three had childhood-onset generalized epilepsy with 
generalized tonic-clonic seizures, with one also having atypical absence seizures.  We also 
reviewed available clinical data on five published patients with Bainbridge-Ropers syndrome and 
seizures.  Of the five previously published patients, three also had generalized tonic-clonic 
seizures, one of whom also had possible absence seizures; a fourth patient had absence seizures 
and possible focal seizures.  EEG typically showed features consistent with generalized epilepsy 
including generalized spike-wave, photoparoxysmal response, and occipital intermittent 
rhythmic epileptiform activity.  Bainbridge-Ropers syndrome is associated with childhood-onset 
generalized epilepsy with generalized tonic-clonic seizures and/or atypical absence seizures. 
 
Key Words: ASXL3, Bainbridge-Ropers syndrome, Generalized epilepsy, Atypical absence, 
Photoparoxysmal response 
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1. Introduction 
Bainbridge-Ropers syndrome (OMIM 615485) is caused by de novo heterozygous truncating 
pathogenic variants in ASXL3 (OMIM 615115) (Bainbridge et al., 2013), a gene encoding a sex 
comb-like protein that plays a role in transcriptional regulation (Katoh and Katoh, 2004; 
Srivastava et al., 2016).  The clinical phenotype most commonly involves severe intellectual 
disability, speech difficulties, autistic features, hypotonia, dysmorphic features and early feeding 
difficulties.  Of 28 published patients, seizures were reported in 9 (Bainbridge et al., 2013; 
Balasubramanian et al., 2017; Contreras-Capetillo et al., 2017; Dinwiddie et al., 2013; Hori et al., 
2016; Kuechler et al., 2017; Srivastava et al., 2016).  Although seizures occur in ~1/3 of 
Bainbridge-Ropers cases, the epileptology has not yet been thoroughly characterized. 
 
Here, we investigated the epilepsy phenotype in Bainbridge-Ropers syndrome.  We report 3 
patients with novel ASXL3 pathogenic variants and seizures, as well as additional epileptology 
data on 5 previously published individuals. 
 
2. Methods 
We were referred a patient with Bainbridge-Ropers syndrome, and performed electroclinical 
epilepsy phenotyping.  This study was approved by the Human Research Ethics Committee of 
Austin Health, Project No. H2007/02961.  Informed, written consent was obtained from the 
subject’s parents. 
 
We reviewed clinical and molecular genetic data available on patients reported in the 
DECIPHER database (https://decipher.sanger.ac.uk) with ASXL3 pathogenic variants and 
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seizures (Firth et al., 2009), and obtained additional clinical data from submitting clinicians.  We 
reviewed the literature regarding seizures in Bainbridge-Ropers syndrome, and obtained 
additional clinical data from patients with seizures reported in a 12-patient cohort 
(Balasubramanian et al., 2017).   
 
This study makes use of data generated by the DECIPHER community. A full list of centres who 
contributed to the generation of the data is available from http://decipher.sanger.ac.uk and via 
email from decipher@sanger.ac.uk. Funding for the DECIPHER project was provided by the 
Wellcome Trust. 
 
3. Results 
3.1 Patient #1: A 6-year-old boy was referred with uncontrolled epilepsy and Bainbridge-Ropers 
syndrome with novel NM_030632.1:c.3106C>T, p.Arg1036* ASXL3 variant identified on 
singleton whole exome sequencing.  The variant was considered pathogenic, predicted to result 
in premature protein truncation, and not present in the Genome Aggregation Database 
(gnomAD) or other population databases (Lek et al., 2016).  Sanger sequencing of this variant in 
both parents confirmed the variant was de novo. 
 
His first seizure was afebrile generalized tonic-clonic status epilepticus at age two years.  
Valproate was started and he was seizure-free for 18 months, at which time medication was 
weaned.  He had a brief, self-limited generalized tonic-clonic seizure at 4.5 years, but medication 
was not re-started. 
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At 5.5 years, he began to have paroxysmal episodes of impaired awareness and loss of tone 
(Video).  With these events, his parents first noticed decreased awareness, sometimes with 
dysconjugate gaze, and he appeared to hold his breath.  He then had slow loss of tone, fell to the 
floor, and injured himself with more severe episodes.  The duration of events was < 30 seconds, 
and he had up to 40 events in a day.  The frequency of events did not noticeably change with 
reintroduction of valproate, or initiation of clobazam and lamotrigine. 
 
His awake interictal EEG showed normal background with no epileptiform discharges, though 
occipital intermittent rhythmic delta activity (OIRDA) was often seen (Figure A).  The ictal 
recording during his impaired awareness events initially showed bilateral posterior rhythmic 
delta activity, which often evolved into 5-10 seconds of rhythmic bifrontal sharp-slow discharges 
(Figure B).  Based on the clinical manifestations and EEG correlate, the events were classified as 
atypical absence seizures.  Ethosuximide was started and the frequency of events decreased 
considerably. 
 
He had generalized hypotonia and severe developmental impairment from the first year of life.  
He crawled at 18 months, walked independently at 4 years, and at 6 years, had no spoken words.  
His only episode of regression came at 5.5 years with his onset of frequent seizures.  There were 
no autistic features.  He had hypotonic facies with peri-orbital fullness, full cheeks, an open 
mouth with drooling and a thick lower vermillion, and small ears. 
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3.2 DECIPHER Patients 
A DECIPHER database search found 47 patients with ASXL3 variants identified in the 
Deciphering Developmental Disorders Study (DDD), although this includes patients with 
variants of unknown significance.  Of these individuals, 5 patients with seizures have been 
reported previously and 2 further patients were identified with ASXL3 pathogenic variants and 
seizures.  The available clinical information regarding epileptology, as well as molecular genetic 
data, are in Table (patients #2, 3).  Both patients had generalized tonic-clonic seizures alone and 
phenotypes consistent with childhood-onset generalized epilepsy.   
 
3.2.1 Patient #2: A 17-year-old male was evaluated at 3 months, for poor feeding, visual 
inattention, failure to thrive and possible seizures. Subsequently, he developed spasticity 
affecting his lower limbs, nystagmus, scoliosis, and multiple contractures of upper and lower 
limbs. He required surgical decompression for an ulnar nerve compression.  His height, weight 
and head circumference were < 0.4th centile and he had severe global developmental impairment 
and was non-verbal. 
 
In early childhood, he was investigated for stimulus-sensitive shuddering episodes with eyelid 
flickering, usually associated with excitement or with auditory or visual stimulation. An EEG 
showed generalised spike-wave discharges with photosensitivity.  However, a trial of valproate 
resulted in overall deterioration in his behaviour, did not modify the shaking episodes, and was 
discontinued.   Subsequent EEG telemetry captured the episodes of shaking, and suggested the 
events were unlikely to be epileptic. At 13 years, he presented with two episodes in a 24-hour 
period consistent with generalised tonic-clonic seizures, occurring during a wean of codeine 
 7 
 
 
 
prescribed to manage generalised pain symptoms. He was commenced on lamotrigine and 
remained seizure-free until 16 years when he had a further episode during sleep that was thought 
to be a seizure. Subsequent concerns that the lamotrigine was affecting his mood led to a change 
to levetiracetam, discontinued at 18 years.  He remained seizure-free at last assessment. 
 
Whole exome sequencing identified a de novo ASXL3 splice site variant 
(NM_030632.2:c.3039+1G>A), not present in gnomAD, and predicted to severely decrease 
splice signal based on the in silico tool, MaxEntScan (Yeo and Burge, 2004). 
3.2.2 Patient #3:  A 7-year-old boy had mild global developmental impairment and autism 
spectrum disorder.  He presented with prolonged generalized tonic-clonic seizures, including 
status epilepticus, at 4 years.  Seizures typically occurred every 4-6 months.  Valproate was 
initiated and reduced seizure frequency.  His physical examination was notable for borderline 
microcephaly, with height and weight at ~90
th
 percentile, and head circumference the 2
nd
.   
Whole exome sequencing identified a de novo ASXL3 loss-of-function variant 
(NM_030632.2:c.3313_3316delCAGA, p.Thr1106ArgfsTer36), not present in gnomAD. 
3.3 Previously Published Cases 
In the 12-patient cohort of Balasubramanian et al, one additional patient has experienced seizures 
in addition to the four noted in the original table.  The available clinical data are summarized in 
Table (patients #4-8).  Four patients had one or both of absence and generalized tonic-clonic 
seizures, with seizure types not known for one patient.  One patient only had generalized tonic-
clonic seizures occurring with fever; one patient was reported to have focal seizures but further 
details were not available.  Interictal EEG results were available for one patient, showing a 
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normal background with both focal and generalized epileptiform discharges.  Data on medication 
response was available for two patients; both responded to valproate with one confirmed to be 
seizure-free for the past two years.  Notably, patient #5 had behavioural hyperventilation 
episodes, though these had not been associated with seizures. 
 
4. Conclusions 
We present three patients with Bainbridge-Ropers syndrome, all of whom have generalized 
epilepsy with childhood-onset generalized tonic-clonic seizures.  Patient #1 also had unusual 
absence seizures, involving altered patterns of breathing that could be mistaken for breath-
holding or hyperventilation events.  Although detailed epilepsy phenotyping was not available 
for the patients published in the Balasubramanian cohort, the available data is also consistent 
with generalized epilepsy with generalized tonic-clonic and/or absence seizures.  These findings 
indicate that the typical epilepsy phenotype in Bainbridge-Ropers syndrome is childhood-onset 
generalized epilepsy with absence and generalized tonic-clonic seizures. 
 
Understanding the epileptology of Bainbridge-Ropers syndrome is of clinical importance, as 
ASXL3 variation was frequently identified in a trio whole exome sequencing study of children 
with non-specific intellectual disability (Balasubramanian et al., 2017; Wright et al., 2015).  A 
better knowledge of the typical epilepsy presentation and course will inform diagnosis, 
counseling and treatment decisions. 
 
From a molecular genetic perspective, we present the first patient with a de novo splice site 
variant, as the cause of the patient’s severe developmental impairment and epilepsy.  All 
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previous cases of Bainbridge-Ropers syndrome have occurred with variants leading to premature 
protein truncation, as was the case with our patients #1 and 3 (Balasubramanian et al., 2017). 
 
The observation of generalized epilepsy in Bainbridge-Ropers syndrome has important 
implications for our understanding of the underlying pathophysiology of this disorder.  The 
disrupted protein, ASXL3, is involved in transcriptional regulation (Katoh and Katoh, 2004; 
Srivastava et al., 2016), and the recognition of the epilepsy phenotype may give clues as to 
which downstream pathways are disrupted.  The genes implicated in the generalized epilepsies 
are primarily related to ion channels and neurotransmitter receptors, such as sodium channels and 
GABA receptors (Helbig, 2015), and it may be that altered transcriptional regulation with 
ASXL3 dysfunction leads to disruption of these proteins.  Delineating the affected pathways 
could have treatment implications; however, quantitative transcriptional and functional studies 
are first required to confirm this hypothesis. 
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Figure Legend 
Figure - EEG recordings of Patient #1 at 6 years of age. (A) Interictal EEG shows symmetric 
occipital intermittent rhythmic delta activity (OIRDA).  Excessive low amplitude beta activity is 
also noted over the anterior regions, reflecting medication effects.  (B) Ictal EEG during an 
atypical absence seizure.  There is initial rhythmic delta activity over the posterior head regions, 
which evolves into 6-7 seconds of slow spike-wave (~1.25 Hz) rhythmic discharges which are 
maximal over the frontal regions. 
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